Literature DB >> 16677689

A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up.

Hanna Sallinen1, Maarit Anttila, Johanna Narvainen, Maija-Riitta Ordén, Kirsi Ropponen, Veli-Matti Kosma, Seppo Heinonen, Seppo Yla-Herttuala.   

Abstract

OBJECTIVE: Typically, human ovarian cancer is widely disseminated at the time of diagnosis and shows extremely poor prognosis. Experimental animal models that mimic human ovarian cancer are often incomplete when compared to the full spectrum of the human disease with regard to its histological hallmarks such as the spread of carcinoma, its ability to seed the peritoneal cavity and formation of ascites. We have established and characterized a new animal model for human ovarian cancer in nude mouse.
METHODS: A new cell line SKOV-3m was injected intraperitoneally in nude mice. Mice were divided in two groups A and B, which received 1 x 10(7) and 2 x 10(7) cells, respectively. Histology, immunohistochemistry, magnetic resonance imaging and ultrasound were used to analyze tumors.
RESULTS: All mice had tumors within 18 days and histologically they resembled poorly differentiated human cystadenocarcinomas with bloody ascites. Mean survival of the mice was 42+/-14 and 21+/-2 days in groups A and B, respectively. Magnetic resonance imaging and ultrasound were used to confirm the presence of tumors and to monitor their growth without sacrificing the animals.
CONCLUSION: This new xenograft model accompanied by noninvasive imaging is highly reproducible and likely to be very useful in testing new treatment strategies for ovarian cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16677689     DOI: 10.1016/j.ygyno.2006.03.030

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents.

Authors:  Denise C Connolly; Harvey H Hensley
Journal:  Curr Protoc Pharmacol       Date:  2009-06-01

2.  Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.

Authors:  Hanna Sallinen; Maarit Anttila; Johanna Narvainen; Jonna Koponen; Kirsi Hamalainen; Ivana Kholova; Tommi Heikura; Pyry Toivanen; Veli-Matti Kosma; Seppo Heinonen; Kari Alitalo; Seppo Yla-Herttuala
Journal:  Mol Ther       Date:  2008-12-02       Impact factor: 11.454

3.  Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats.

Authors:  Allison C Sharrow; Brigitte M Ronnett; Christopher J Thoburn; James P Barber; Robert L Giuntoli; Deborah K Armstrong; Richard J Jones; Allan D Hess
Journal:  J Ovarian Res       Date:  2010-03-31       Impact factor: 4.234

4.  Assessment of anti-inflammatory tumor treatment efficacy by longitudinal monitoring employing sonographic micro morphology in a preclinical mouse model.

Authors:  Sanjay Tiwari; Jan H Egberts; Olena Korniienko; Linda Köhler; Anna Trauzold; Claus C Glüer; Holger Kalthoff
Journal:  BMC Med Imaging       Date:  2011-06-23       Impact factor: 1.930

Review 5.  Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application.

Authors:  Alessandra Ciucci; Marianna Buttarelli; Anna Fagotti; Giovanni Scambia; Daniela Gallo
Journal:  Cell Mol Life Sci       Date:  2022-06-16       Impact factor: 9.207

6.  Establishment of a new representative model of human ovarian cancer in mice.

Authors:  Jianjun Zhang; Xinlian Chen; Gang Shi; Xiaoyan Xie; Hongqian Liu; Xuemei Zhang; Yi Lai; Yan Zuo; Zhong Chen; Shanling Liu; He Wang
Journal:  J Ovarian Res       Date:  2013-02-06       Impact factor: 4.234

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.